Table 2 The risk factors for higher prevalence of HK (> 5.0 mmol/L).

From: Prevalence, practice pattern, and mortality of hyperkalemia in Chinese patients undergoing hemodialysis in the visualize HD study

Variables (percentage)

Univariate OR

(95% CI)

P

Multivariate OR (95% CI)

P

Age (≥ 65 years)

0.978 (0.957, 1.000)

0.048

  

Sex (male)

1.005 (0.979, 1.031)

0.720

  

Dialysis frequency ≥ 3 (times/ week)

0.994 (0.986,1.001)

0.106

0.986 (0.976,0.996)

0.007

Dialysis vintage ≥ 5 (years)

1.008 (0.992,1.024)

0.379

  

Hemoglobin ≥ 90 (g/L)

1.027 (1.004, 1.050)

0.022

1.032 (1.003,1.062)

0.033

Albuminbu ≥ 40 (g/L)

0.911 (0.860,0.965)

0.024

1.026 (1.009,1.044)

0.003

Phosphorus (mmol/L)

1.039 (1.013, 1.066)

0.003

  

RAASi usage

1.001 (0.993, 1.009)

0.120

  

Diuretics usage

1.013 (0.983, 1.044)

0.408.

  

Potassium binders

1.035 (1.002, 1.069)

0.036

  

patients’ treatment time > 210 min (yes/no)

0.798 (0.525,1.212)

0.750

  
  1. CI Confidence interval, HK hyperkalemia, RAASi included angiotensin-converting enzyme inhibitor, angiotensin receptor blocker, mineralocorticoid receptor antagonist, and angiotensin receptor/neprilysin inhibitor (ARNI).
Back to article page